Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

Capricor Therapeutics, Inc. (CAPR) presented data from its HOPE-3 open-label extension study and provided an update on its Deramiocel product candidate for Duchenne Muscular Dystrophy (DMD) in a recent call.

The company reported positive results from the HOPE-3 study, with patients showing improvements in cardiac and skeletal muscle function. CAPR also noted that it is on track to initiate a Phase 3 study for Deramiocel in the first half of 2027.

The company's CEO, Linda Marbán, discussed CAPR's plans to advance its pipeline and create value for shareholders.